121.67 +0.34 (0.28%)
After hours: 7:22PM EDT
|Bid||121.66 x 100|
|Ask||121.73 x 200|
|Day's Range||120.80 - 124.54|
|52 Week Range||96.93 - 147.17|
|PE Ratio (TTM)||37.58|
|Earnings Date||Oct 26, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||154.38|
Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.
Celgene toppled to a four-month low Friday after it scrapped trials in Crohn's disease after a late-stage failure.
On another record day for the major benchmarks, shares of Skechers skyrocketed on earnings and Celgene tumbled after discontinuing a drug trial.
Shares of Celgene (CELG) plunged to the bottom of the S&P 500 today after the drug maker abandoned clinical trials testing its experimental drug Mongersen as a treatment for Crohn’s disease. The stock fell almost 10.8% to close at $121.33 on a day when the S&P 500 posted a 0.5% gain, making Celgene the worst-performing stock in the index. Mongersen was a high-profile drug in Celgene’s pipeline.
A disappointing late-stage trial failure is causing shares to tumble, but there's a lot going on at this company that could pan out for investors.
BMO Capital Markets’ M. Ian Somaiya takes a look at the biotech sector on Friday, writing that another strong quarter could help the stocks keep climbing. Somaiya writes that he expects solid results from ...
Celgene’s (CELG) efforts to reduce its dependence on the blood cancer drug Revlimid suffered a setback today when the drug maker Celgene said it would abandon testing mongersen, a big treatment for Crohn’s disease. The drug maker announced that it would stop two trials, and would not initiate a third study following a risk-benefit analysis by a data monitoring committee. Celgene says there were “no meaningful safety imbalances” identified in the committee’s analysis.
Stocks jumped at the starting bell Friday, as global markets rebounded and earnings news rolled in.
Stocks look set for a higher open this morning after the Senate passed a budget resolution that could clear the way for tax cuts. S&P 500 futures have, while Dow Jones Industrial futures have. Nasdaq Composite ...
Celgene's partnership strategy gives it exposure to multiple companies' research on next-generation cell therapy.
Celgene Corp. was downgraded to neutral at Baird Equity Research on Friday after the drugmaker abandoned three Crohn's disease drug trials late Thursday. Baird analyst Brian Skorney also lowered the company's ...
Stock futures rose Friday morning after the Senate approved a budget resolution that paves the way for tax cuts. Several top-rated stocks already were moving late.
Celgene stock fell late Thursday after the biotech discontinued a pair of trials for a late-stage drug to treat Crohn's disease.
Celgene Corp. shares dropped in the extended session Thursday after the biotech company said it would discontinue two clinical trials for a Crohn's disease treatment and not start a third. Celgene shares ...
Celgene Corporation today announced that the GED-0301 phase III REVOLVE trial in Crohn’s disease and the extension trial will discontinue.
Celgene Corporation today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 and 5 receptor modulator, in relapsing multiple sclerosis were accepted for the MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting, which is being held in Paris, October 25-28, 2017.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals